Dr. Yong recommends that Thailand should use LAAB antibody drug to treat COVID-19.

13 Dec. 2022 – Dr. Yong Phuwarawan, Head of the Center, Specializing in Clinical Virology Department of Pediatrics Faculty of Medicine Chulalongkorn University Facebook postindicate that

In the early stages when there was no vaccine We also use antibodies to help in the treatment. For example, the use of plasma from people who have already recovered from covid 19 disease, which has antibodies, is like giving a serum. or monoclonal antibodies to help in the treatment

Later, when there was a vaccine to create antibody immunity. There is no need for plasma antibodies because the body can make antibodies from vaccines. or infection We will use it in people who are not vaccinated and have never been infected before.

Viruses continue to mutate, resulting in antibodies synthesized or created with the original strain. less efficient or cannot be used Until reaching the current strain, Omicron BA.2.75, the antibody that is still acceptable in our country would be The supplied antibody called LAAB (Evushield) and further, the virus if altered to Subspecies BQ.1, BQ.1.1 or XBB are even less effective.

use of antibodies Available in our homes should now be given in people with low immunity. Especially those who have been vaccinated and their immunity is not responding. Including patients with chronic renal failure Immune suppressant organ replacement patients cancer patients undergoing treatment with drugs or radiation that affect immunity There are quite a number.

LAAB antibodies can also be used in the treatment. similar to the original plasma In risk groups that have never been vaccinated before or received 1 or 2 doses of vaccine because the immune level may be low or not. Initial administration of antibodies upon infection will reduce the severity of the disease and mortality rates can be reduced.

The Ministry of Public Health currently has enough LAABs to provide such patients. The drug is very safe.

And now the disease is on the rise. Patients in the aforementioned vulnerable groups Therefore, antibodies should be given strongly. Including when there is an infection, it should be treated with antibodies. to reduce the severity of disease and death

medicines currently available should hurry to use in this ripple should not be stored because when the virus has mutated It will not work. or not useful

add friends

Leave a Replay